Global Blood Therapeutics Inc GBT:NASDAQ

Last Price$26.64Cboe Real-Time Last Sale as of 10:18AM ET 1/27/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.13(0.49%)
Bid (Size)$26.51 (100)
Ask (Size)$26.72 (100)
Day Low / High$26.59 - 28.17
Volume181.2 K
 

View Biotechnology IndustryPeer Comparison as of 01/27/2022

 

Global Blood Therapeutics Inc ( NASDAQ )

Price: $26.64
Change: +0.13 (0.49%)
Volume: 181.2 K
10:18AM ET 1/27/2022
 
 

Agios Pharmaceuticals Inc ( NASDAQ )

Price: $30.95
Change: -0.05 (0.16%)
Volume: 55.2 K
10:17AM ET 1/27/2022
 
 

ChemoCentryx Inc ( NASDAQ )

Price: $25.32
Change: -0.14 (0.55%)
Volume: 96.6 K
10:15AM ET 1/27/2022
 
 

Travere Therapeutics Inc ( NASDAQ )

Price: $26.09
Change: -0.47 (1.77%)
Volume: 60.6 K
10:18AM ET 1/27/2022
 
 

Allogene Therapeutics Inc ( NASDAQ )

Price: $11.22
Change: 0.00 (0.00%)
Volume: 128.6 K
10:18AM ET 1/27/2022
 

Read more news Recent News

RBC Lifts Price Target on Global Blood Therapeutics to $65 From $64, Maintains Outperform Rating
8:12AM ET 1/06/2022 MT Newswires

Global Blood Therapeutics (GBT) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $30 to...

Global Blood Therapeutics Wins US FDA Nod for Expanded Indication of Oxbryta in Children
3:22PM ET 12/17/2021 MT Newswires

Global Blood Therapeutics (GBT) said Friday the US Food and Drug Administration granted accelerated approval for an expanded indication of oxbryta tablets...

Global Blood Gets European Medicines Agency Committee's Backing for Sickle Cell Disease Drug Candidate
11:10AM ET 12/17/2021 MT Newswires

Global Blood Therapeutics (GBT) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended granting the...

Sector Update: Health Care Stocks Continue Gaining into Wednesday Close
4:07PM ET 12/15/2021 MT Newswires

Health care stocks were finishing near their intra-day highs, with the NYSE Health Care Index rising 2.0% while the SPDR Health Care Select Sector ETF...

Company Profile

Business DescriptionGlobal Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. View company web site for more details
Address181 Oyster Point Boulevard
South San Francisco, California 94080
Phone+1.650.741.7700
Number of Employees171
Recent SEC Filing01/27/20228-K
President, Chief Executive Officer & DirectorTed W. Love
Senior Vice President-OperationsNazila Habibizad
Chief Financial & Accounting OfficerJeffrey S. Farrow
Executive VP, Head-Research & DevelopmentKim Smith-Whitley

Company Highlights

Price Open$26.96
Previous Close$26.51
52 Week Range$24.61 - 52.49
Market Capitalization$1.7 B
Shares Outstanding64.4 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/23/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.45
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-154.11%
Return on Equity-79.04%

Analyst Ratings as of 12/06/2021

Buy
17
Overweight
0
Hold
4
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset